- Global Pharma News & Resources

CENTOGENE Reveals Growth of Rare Hereditary Disease Knowledge Base

DGAP-News: CENTOGENE AG / Key word(s): Miscellaneous

01.07.2019 / 15:00
The issuer is solely responsible for the content of this announcement.

CENTOGENE Reveals Growth of Rare Hereditary Disease Knowledge Base

Driving Accelerated Diagnosis and Treatment Development

Cambridge, MA, USA & Rostock, Berlin, GERMANY, 01 July 2019 - CENTOGENE today revealed the growth in its knowledge-base of rare hereditary diseases. In a recent update to CentoMD(R) -
CENTOGENE's data repository of epidemiologic, phenotypic and clinical data - the Company found that since December 2018 the number of analyzed cases has grown by 16% to more than 360,000, and the number of total variants has increased by 26% to 9.3 million. This now covers data from over 120 countries, underscoring the important ethnic diversity of CENTOGENE's knowledge-base.

For comparison purposes, ClinVar - the freely available database - contains 510,000 variants as of June 2019, while HGMD Pro contains 255,000 variants as of January 2019.

"We believe CentoMD(R) to be the world's largest curated mutation database for rare diseases, and an important bridge between genetic variants and clinical interpretations - with a significant number of unpublished variants," said Dr. Arndt Rolfs, CEO CENTOGENE. "By following a strict data curation process, we are providing highly accurate data relevant to clinical diagnosis and decision-making."

"Our detailed genetic, proteomic and metabolic analysis is the key to fueling the knowledge base of rare disease patient populations, helping to drive CENTOGENE's biomarker development program, and support our pharmaceutical partners in accelerating the development of orphan drugs. Ultimately our knowledge and expertise are for the benefit of our rare disease patients to help end the diagnostic odyssey that so many of them face." Rolfs added.

CentoMD(R) contains data that combines variant information with proteomic and metabolomics information, in particular for high-throughput genes. Classification of variants in CentoMD(R) follows the American College of Medical Genetics and Genomics guidelines for uniform variant classification. With a highly qualified and standardized curation process, CentoMD(R) provides high-quality clinical interpretations of newly identified variants and also ensures that changes in variant classification will be communicated and reflected in clinical interpretations in a timely manner.

More information on CentoMD(R) (v5.4) can be found here.

- ends -


CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including our epidemiological and clinical heterogeneity and our innovative biomarkers.

As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and creating hope for our patients with rare diseases and their families.



Ross Bethell
Director, Corporate Communications

01.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Editor Details

Last Updated: 01-Jul-2019